Skip to main content
Nebiyat Eskndir on Muck Rack

Nebiyat Eskndir

As seen in: Nature, BioRxiv, Cell Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Nebiyat

Contact Nebiyat, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial

|
By Rebecca Porter, Yinglu Zhou, Nebiyat Eskndir, Martin Hayes, Madeline Polak, Elizabeth Lee, Carolyn Krasner, Susana Campos, Alexi A. Wright, Joyce Liu, Elizabeth Stover, Hannah Sawyer, Niya Xiong, Kathleen L. Pfaff, Scott J. Rodig, Nabihah Tayob, Susan Zweizig, Veena John, Ursula Matulonis, Panagiotis A. Konstantinopoulos, Jennifer Veneris
| Nature Verified
Abstract Immune checkpoint inhibitors (ICI) synergize preclinically with antibody drug conjugates (ADC), harboring anti-tubulin maytansinoid payloads. We conducted an investigator-initiated, single-arm, phase 2 trial of mirvetuximab soravtansine (MIRV), a folate receptor alpha (FOLR1/FRα)-targeting ADC with the maytansinoid payload, DM4, combined with pembrolizumab in female patients with recurrent FOLR1-expressing serous endometrial cancer (EC, NCT03835819).
Open in Who Shared Issue with article?

CRATER tumor niches facilitate CD8+ T cell engagement and correspond with immunotherapy success

|
By Aya Ludin, Georgia L. Stirtz, Asaf Tal, Ajit J Nirmal, Kathleen L. Pfaff, Michael Manos, Naomi R. Besson, Nebiyat Eskndir, Billie JD Porter, Stephanie Jones, Hannah Faulkner, Qiyu Gong, Sophia B. Liu, Irving Barrera, Lijian Wu, Cecilia Pessoa Rodrigues, Cecília Rodrigues, Aditi Sahu, Elizabeth R. Jerison, Joao V Alessi, Biagio Ricciuti, Douglas Richardson, Jodi Weiss, Hadley Moreau, Alexander B. Afeyan, James Sefton, Yi Zhou, Hannah Cole, Miguel Cordova, Liang Deng, Milind Rajadhyaksha, Stephen R. Quake, Mark Awad, fei chen, Kai W. Wucherpfennig, Peter K. Sorger, F. Stephen Hodi, Scott J. Rodig, George Murphy, Leonard I. Zon, Meredith E. Stanhope, Wyatt D. McCall, Emily Formato
| Cell Press Verified
Keywords melanoma immune response immunotherapy zebrafish CD8+ T cells cancer Introduction Immune checkpoint blockade (ICB) cancer therapy, re-activating CD8+ T cells against tumors, has significantly increased patients’ life expectancy and survival.1,2 ICB initiates CD8+ T cell infiltration and results in necrosis, fibrosis, and shrinkage.
Open in Who Shared Issue with article?

DNA damage causes ATM-dependent heterochromatin loss leading to nuclear softening, blebbing, and rupture

|
By Nebiyat Eskndir, Mai T. Pho, Manseeb Hossain, Marilena L Currey
| BioRxiv
Abstract The nucleus must maintain stiffness to protect the shape and integrity of the nucleus to ensure proper function. Defects in nuclear stiffness caused from chromatin and lamin perturbations produce abnormal nuclear shapes common in aging, heart disease, and cancer. Loss of nuclear shape via protrusions called blebs leads to nuclear rupture that is well-established to cause nuclear dysfunction, including DNA damage.
Open in Who Shared Issue with article?
See all 4 articles